BeOne Medicines (NASDAQ:ONC) Posts Earnings Results, Beats Estimates By $1.30 EPS

BeOne Medicines (NASDAQ:ONC) released its earnings results on Thursday. The company reported $3.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30, Zacks reports. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q3 revenue and profitability accelerated: Product revenue rose 33% year over year to about $1.9 billion, while GAAP operating income increased 157% to $419 million. BeOne raised its 2026 revenue outlook to $6.9 billion–$7.0 billion and increased its operating-income guidance.
• BRUKINSA continued to drive growth: Global sales grew 34% to $1.4 billion, with U.S. sales exceeding $1 billion for the first time. Management pointed to strong new-patient starts and real-world evidence, while noting that U.S. sales benefited by about $50 million from order timing.
• Pipeline progress broadened across hematology and solid tumors: BeOne reported encouraging early data for several solid-tumor programs and advanced its B7-H4 ADC into a Phase III trial. The company also said its BTK degrader met the primary endpoint in a Phase II CLL study and that its treatment-naive mantle-cell lymphoma application received FDA priority review.
• Some expected returns may take longer, and investment will remain high: After FDA discussions, BeOne shifted its planned accelerated-approval filing for the BTK degrader in relapsed/refractory CLL to mid-2027, citing a request for additional follow-up. Management expects 2027 operating-expense growth to remain substantial, moderating the pace of margin expansion; it also flagged potential revenue pressure for XGEVA and KYPROLIS from biosimilars and possible China VBP inclusion.

BeOne Medicines Stock Up 2.5%

ONC traded up $9.47 on Thursday, reaching $387.25. The company’s stock had a trading volume of 959,362 shares, compared to its average volume of 395,963. The stock has a 50 day moving average of $362.80 and a two-hundred day moving average of $325.98. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $42.52 billion, a price-to-earnings ratio of 66.51 and a beta of 0.63. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $405.00.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 earnings per share of $3.64, above the $2.34 consensus estimate. Reports also said revenue and adjusted earnings rose, and the company increased its 2026 revenue outlook—signals of stronger performance and improved expectations. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review for a BRUKINSA combination in first-line mantle cell lymphoma. A potential label expansion could broaden the drug’s use, though priority review is not an approval. FDA Priority Review for BRUKINSA Combination

Wall Street Analyst Weigh In

Several research analysts have commented on ONC shares. Weiss Ratings upgraded shares of BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Nomura lifted their price objective on shares of BeOne Medicines from $454.75 to $484.91 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a research note on Thursday, October 1st. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Finally, Truist Financial increased their target price on BeOne Medicines from $418.00 to $420.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, BeOne Medicines currently has a consensus rating of “Buy” and a consensus price target of $424.26.

Insider Activity at BeOne Medicines

In related news, CEO John Oyler sold 115,011 shares of BeOne Medicines stock in a transaction on Monday, August 10th. The shares were sold at an average price of $357.87, for a total transaction of $41,158,986.57. Following the sale, the chief executive officer directly owned 125,799 shares in the company, valued at $45,019,688.13. This trade represents a 47.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of BeOne Medicines stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 376,373 shares of company stock valued at $134,848,154. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.